Breaking New Ground in Addiction Treatment
Episode Overview
A new protocol allows starting buprenorphine injectables without stopping fentanyl. Over-the-counter magic mushrooms often lack actual psilocybin. Cigarette filters may be more harmful than beneficial. The study focuses on low-threshold settings for opioid use disorder. Outreach is crucial for reaching homeless patients.
"Basically none of the over-the-counter magic mushrooms being sold actually had psilocybin in them."
How do people find strength in their journey to sobriety? In this episode of Addiction Medicine Journal Club, Dr. John Keenan and Dr. Sonya Del Tredici tackle the complexities of starting buprenorphine injectables without the need to halt fentanyl or experience opioid withdrawal. This innovative protocol, studied by the Downtown Emergency Services Center and the University of Washington, is a game-changer for those struggling with opioid use disorder, especially in low-threshold settings.
You'll hear about the challenges faced by patients who are homeless and battling addiction, and how this new approach could offer them a lifeline. Beyond buprenorphine, the hosts delve into the curious world of over-the-counter magic mushrooms and the surprising findings that none of the products tested contained actual psilocybin. They also discuss the environmental impact of cigarette filters and why they might be more harmful than helpful.
The episode is a fascinating blend of humour, science, and practical advice that will leave you thinking about the future of addiction treatment. So, how can this new protocol transform lives? Tune in to find out!